Literature DB >> 26119800

Infantile Bullous Pemphigoid Treated Using Intravenous Immunoglobulin: Case Report and Review of the Literature.

Burak Tekin1, Ayşe Deniz Yücelten1.   

Abstract

We report a 5-month-old girl diagnosed with bullous pemphigoid who initially did not respond to systemic corticosteroids and dapsone but rapidly improved after the addition of intravenous immunoglobulin (IVIG) infusions. A literature search revealed anecdotal cases of infantile bullous pemphigoid treated with IVIG, although variable treatment regimens were used, and some resistant cases required additional medications such as rituximab for clinical remission.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26119800     DOI: 10.1111/pde.12635

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  5 in total

Review 1.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Recalcitrant infantile bullous pemphigoid successfully treated with cyclosporine.

Authors:  Efrat Bar-Ilan; Andrea Izabella Gál; Klára Veres; Anna Solti; Petra Ágnes Ferge; Tímea Dimény; Norbert Kiss; Zsuzsanna Szalai
Journal:  JAAD Case Rep       Date:  2022-09-13

Review 3.  Bullous Diseases in Children: A Review of Clinical Features and Treatment Options.

Authors:  Brittney Schultz; Kristen Hook
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

4.  Autoimmune Bullous Disease in Childhood.

Authors:  Andac Salman; Burak Tekin; Deniz Yucelten
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

5.  Two infants with blistering rashes originating on acral sites as a presenting sign of infantile bullous pemphigoid.

Authors:  Brent Folsom; Tom Raisanen; Milad Eshaq
Journal:  JAAD Case Rep       Date:  2020-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.